Pan-RAS molecular glue posts 62% uORR in NSCLC Phase 1; the bet is whether Phase 3 confirms it before Revolution Medicines' patent suit shuts it down

Updated 35d ago

Erasca is a clinical-stage company developing a targeted cancer drug for lung cancer caused by KRAS mutations that is not yet approved.

ERAS-0015, a pan-RAS molecular glue targeting KRAS-mutant lung cancer and pancreatic cancer, posted 62% unconfirmed response rates in second-line NSCLC and 57% in PDAC from Phase 1 dose escalation. The thesis holds if Phase 3 replicates those signals and Revolution Medicines' patent infringement and trade-secret claim fails to block development. A single-arm Phase 3 filing in NSCLC, without a randomized control, carries meaningful approvability risk independent of whether the drug works.

Status

Challenged

Conviction

Current Thesis Drivers

62% uORR 2L+ NSCLC, 57% uORR 2L+ PDAC, no DLTs
$632.5M raised July 2026; ~4+ years runway at current burn
Approvability on single-arm Phase 3 data unresolved
RevMed patent/trade-secret suit demands development cessation

What could change the thesis?

RevMed litigation ruling: dismissed clears path, injunction ends program
Phase 3 NSCLC initiation: enrollment confirms Phase 1, regulatory rejection stalls
PDAC Phase 3 readout: hit expands thesis, miss narrows it to NSCLC alone

Generated from public SEC filings and disclosures. For informational purposes only — not investment advice. Always conduct your own research before making investment decisions.

Thesis log

Tracked in real time as it happened — not reconstructed after the fact

Key value driver

The most decisive event ahead

Bull and bear case

Both sides of the thesis, argued

Pipeline

2 programs · 6 catalysts

Stress Test